cai: the income statement

MyFinsight

Caris Life Sciences, Inc. (CAI)

For the quarter ending 2025-06-30, CAI made $181,398K in revenue. -$517,197K in net income. Net profit margin of -285.12%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

	2025-06-30
Total revenue	181,398
Selling and marketing expense	42,260
Research and development expense	25,047
General and administrative expense (see note 10)	64,367
Cost of services-Pharma Research And Development Services	2,392
Cost of services-Molecular Profiling Services	65,321
Total costs and operating expenses	199,387
Loss from operations	-17,989
Other expense, net	-18,341
Interest income	1,618
Interest expense	19,208
Changes in fair value of financial instruments	-17,870
Total other income (expense), net	-53,801
Loss before income taxes and provision for income taxes	-71,790
Provision for income taxes	-
Net income (loss)	-71,790
Adjustments of redeemable convertible preferred stock to redemption value	60,971
Deemed dividend from series d redeemable convertible preferred stock (see note 6)	384,436
Net loss attributable to common shareholders basic	-517,197
Net loss attributable to common shareholders diluted	-517,197

Net loss per share attributable to common shareholders - basic (in dollars per share)	-7.97
Net loss per share attributable to common shareholders - diluted (in dollars per share)	-7.97
Weighted-average shares used in computing net loss per share attributable to common shareholders - basic (in shares)	64,918,988
Weighted-average shares used in computing net loss per share attributable to common shareholders - diluted (in shares)	64,918,988

Unit: Thousand (K) dollars (except for numbers of shares and EPS)